Jeremy Whitson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jeremy Whitson has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- David J. Marcinek
Department of Radiology University of Washington Seattle Washington USA
1 shared publication - Dongsheng Duan
Department of Molecular Microbiology and Immunology, School of Medicine, University of Missouri
1 shared publication - Ellen K. Quarles
Department of Pathology, University of Washington, Seattle, WA, USA
1 shared publication - Gennifer E. Merrihew
University of Washington
1 shared publication - Hazel H. Szeto
Social Profit Network Research Lab, Menlo Park, California
1 shared publication - Henk Granzier
Department of Cellular and Molecular Medicine, University of Arizona
1 shared publication
Latest Publications
- Open Access
- 2 January 2020
- Published by Cold Spring Harbor Laboratory in bioRxiv
Late-life restoration of mitochondrial function reverses cardiac dysfunction in old mice
Diastolic dysfunction is a prominent feature of cardiac aging in both mice and humans. We show here that 8-week treatment of old mice with the mitochondrial targeted peptide SS-31 (elamipretide) can substantially reverse this deficit. SS-31 normalized the increase in proton leak and reduced mitochondrial ROS in cardiomyocytes from old mice, accompanied by reduced protein oxidation and a shift towards a more reduced protein thiol redox state in old hearts. Improved diastolic function was concordant with increased phosphorylation of cMyBP-C Ser282 but was independent of titin isoform shift. Late-life viral expression of mitochondrial-targeted catalase (mCAT) produced similar functional benefits in old mice and SS-31 did not improve cardiac function of old mCAT mice, implicating normalizing mitochondrial oxidative stress as an overlapping mechanism. These results demonstrate that pre-existing cardiac aging phenotypes can be reversed by targeting mitochondrial dysfunction and implicate mitochondrial energetics and redox signaling as therapeutic targets for cardiac aging.
- 2 January 2020
- Published by Cold Spring Harbor Laboratory in bioRxiv
Open AccessLate-life restoration of mitochondrial function reverses cardiac dysfunction in old mice
Diastolic dysfunction is a prominent feature of cardiac aging in both mice and humans. We show here that 8-week treatment of old mice with the mitochondrial targeted peptide SS-31 (elamipretide) can substantially reverse this deficit. SS-31 normalized the increase in proton leak and reduced mitochondrial ROS in cardiomyocytes from old mice, accompanied by reduced protein oxidation and a shift towards a more reduced protein thiol redox state in old hearts. Improved diastolic function was concordant with increased phosphorylation of cMyBP-C Ser282 but was independent of titin isoform shift. Late-life viral expression of mitochondrial-targeted catalase (mCAT) produced similar functional benefits in old mice and SS-31 did not improve cardiac function of old mCAT mice, implicating normalizing mitochondrial oxidative stress as an overlapping mechanism. These results demonstrate that pre-existing cardiac aging phenotypes can be reversed by targeting mitochondrial dysfunction and implicate mitochondrial energetics and redox signaling as therapeutic targets for cardiac aging.